Abcuro reels in $155M to test an­ti­body's po­ten­tial in rare mus­cle dis­ease, set­ting biotech's 2026 BLA plans

Mass­a­chu­setts biotech Abcuro has se­cured $155 mil­lion to take its bi­o­log­ic through a po­ten­tial­ly reg­is­tra­tional tri­al for a rare mus­cle-wast­ing dis­ease and to an an­tic­i­pat­ed reg­u­la­to­ry ap­proval fil­ing in 2026, CEO Alex Mar­tin told End­points News.

Abcuro’s over­sub­scribed fi­nanc­ing will bankroll a 76-week Phase II/III tri­al of the biotech’s mon­o­clon­al an­ti­body in pa­tients with in­clu­sion body myosi­tis, or IBM. The place­bo-con­trolled tri­al, which be­gun in March, will test two dos­es of ABC008 that is de­liv­ered un­der the skin every eight weeks, med­ical chief Jef­frey Wilkins said in an in­ter­view.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER